T he desensitization (loss of response) and downregulation (loss of receptors) of p-adrenergic receptors (,BAR) have been observed in several cardiac conditions, including certain forms of heart failure and hypertension. The inability of the failing heart to respond to inotropic agents such as catecholamines represents a major clinical problem. The downregulation of 131AR associated with certain forms of heart failure1 has been considered a consequence of the chronic high plasma catecholamine levels associated with this disorder. 
cardiac conditions, including certain forms of heart failure and hypertension. The inability of the failing heart to respond to inotropic agents such as catecholamines represents a major clinical problem. The downregulation of 131AR associated with certain forms of heart failure1 has been considered a consequence of the chronic high plasma catecholamine levels associated with this disorder. The purpose of this review is to examine agonist-induced downregulation of myocardial ,6AR in light of studies suggesting that f31AR are more resistant to downregulation than are /2AR. Potential mechanisms for differential downregulation of flAR subtypes will also be discussed, including the possibility that f82AR on cardiac myocytes are downregulated via coated pits but that f31AR are associated with plasmalemmal vesicles known as caveolae.
Downregulation of Adrenergic Receptors
The process of desensitization and downregulation in response to chronic adrenergic receptor stimulation has been well characterized for R2AR in cultured cells, and these studies are the subject of detailed reviews.2,3 Briefly, isoproterenol (a nonselective ,BAR agonist) induces phosphorylation of the R2AR by cyclic AMP (cAMP)-dependent protein kinase at low agonist concentrations and phosphorylation by ,AR kinase (,lARK) at high agonist concentrations. Phosphorylation is thought to induce uncoupling of the ,AR from the stimulatory G protein, G0 (desensitization). Within minutes, the receptors translocate to a compartment that is inaccessible to hydrophilic ligands (sequestration). The receptors are presumably sequestered in an intracellular vesicular compartment, an ill-defined compartment called the light vesicle fraction. Longer periods of stimulation (1 hour or greater) induce a decrease in total cellular receptors (downregulation), which is probably the result of internalization followed by degradation of the receptor protein in lysosomes.3 Mutagenesis studies suggest a requirement for G, in downregulation23; however, a recent report suggests that interaction with G, is not required for agonist-induced downregulation of the RAR. 4 These workers hypothesize that similar but not identical regions in the cytoplasmic tail of the 32AR are involved in the distinct processes of G protein coupling and receptor downregulation.
Some data suggest that not all adrenergic receptor subtypes respond to continued receptor stimulation in the same way. In cells overexpressing fl2AR and a2-adrenergic receptors (a2AR), agonist stimulation causes the R2AR to internalize, whereas the a2AR remain on the cell surface. Another problem in measuring myocardial PAR stems from the homogenization process itself. To get reliable receptor measurements of ,AR from membrane preparations, the heart must be vigorously homogenized with a blender or Polytron because of its high content of connective tissue. A low-speed spin is generally performed to remove large pieces of tissue. This is followed by another homogenization and a 15 000g spin to remove nuclei and mitochondria. ,AR levels are often determined in this postmitochondrial supernatant or a subsequent postmitochondrial pellet (48 000g). We have compared the distribution of 8AR binding and IAR-stimulated (isoproterenol/GTP) adenylate cyclase activity in subcellular fractions from dog heart ( Table 2 ). The postmitochondrial supernatant contained 12% of total P3AR binding and 3% of total adenylate cyclase activity, whereas the 48 00g membrane fraction contained approximately 2% and 1% of total myocardial I3AR binding and adenylate cyclase Recent data have determined that caveolae are involved in receptor-specific transport of small molecules, such as folate, into the cell, a process called potocytoSiS. 33 It appears that the folate binds to the receptor and the caveola closes at the neck while retaining an association with the plasma membrane. A proton gradient is generated in the closed vesicle that dissociates the folate from the receptor, and the folate is transported across the membrane via an anion carrier.
The presence of immunoreactivity to the 1P3 receptor in caveolae34 and the enrichment of heterotrimeric G proteins, including G, and Gi, in caveolin-rich fractions35 have led to the suggestion that these organelles may play a role in signal transduction.36 It is also noteworthy that cytochemical reactions used to localize PAR-stimulated adenylate cyclase activity have indicated product formation associated with membrane specializations that appear to be caveolae in a variety of cells (including adipocytes, endothelium, and cardiac myocytes).37,38 Cholera toxin, which activates GQ, binds preferentially to caveolae,39 and we have observed the colocalization of caveolin and Gi using immunolabeling in a cultured cell line (unpublished observations). Thus, there is a large body of indirect evidence associating 13AR activity with caveolae but no definitive information regarding ,3AR subtype association with these structures.
Although speculative, the possibility that caveolae contain sequestered receptors should be considered, especially in light of data from Strader et al. 40 They treated frog erythrocytes with isoproterenol (3 hours) followed by either a harsh homogenization or a gentle freeze thaw.
With the harsh treatment, PAR were isolated from a light vesicle fraction on a sucrose gradient, but with gentle treatment the receptors remained with the plasma membrane fraction. This differential pattern of distribution would be consistent with PAR localization to "peninsular vesicles" such as caveolae, which could break off and form free vesicles, depending on the physical forces involved in preparation. Although pharmacologically like a 12AR, the carboxyl terminal region of the frog erytlirocyte B3AR has not been well characterized as to its similarity to mammalian /31AR or RAR. DNA hybridization techniques have indicated that the frog ,AR has some homology with the hamster RAR and that the frog 83AR is weakly homologous to the human 813AR.41 The frog erythrocyte does not have coated pits, eliminating endocytosis as a mechanism for sequestering frog erythrocyte /3AR.42
It is tempting to speculate that R2AR internalize via coated pits and P1AR cluster in caveolae, retaining an association with the plasma membrane; the carboxy terminus may determine localization after agonist stimulation. Quick freezing of skeletal muscle also suggests that unlike coated pits, caveolae are semipermanent features of the plasma membrane43 that do not migrate toward the interior of the cell. Cardiac Another explanation for differential downregulation of J2AR compared with /31AR could be differences in lateral mobility of the receptors. In oocytes overexpressing ,AR subtypes, f2AR were more tightly coupled to G, and adenylate cyclase than fl3AR.48 Parker and Ross49 proposed that the carboxyl tail of the avian ,AR decreases the regulatory activity of the receptor by restricting its lateral mobility. In their studies, truncation of the carboxyl terminal domain of the receptor increased the coupling of the receptor to G, and adenylate cyclase activity. Although the transmembrane regions of the P1AR and 32AR are highly homologous, there is a great deal of diversity in the carboxyl terminal regions. It is possible that PAR subtypes have different lateral mobilities that influence coupling to adenylate cyclase as well as downregulation.
Another mechanism that could explain subtype differences in 8AR downregulation is differences in the rate of synthesis or degradation between subtypes. In this regard, the half-life for 31AR is two times greater than that for 32AR in unstimulated C6 glioma cells. (-ag- onists generally downregulate 3AR, whereas P1AR are relatively resistant to downregulation. This conclusion has important implications regarding heart failure, in which the opposite occurs; there is often a large loss of f31AR with no decrease in f2AR.' The association of heart failure with cardiac sympathetic denervation and high levels of plasma catecholamines has led to the hypothesis that the downregulation of f31AR results from the high plasma catecholamine levels. Data suggest that other mechanisms are involved in the downregulation of f31AR seen in heart failure, possibly related to hypertrophy, necrosis, or other unknown factors. Autoradiographic studies have indicated that 8AR downregulation in human heart failure is observed only in the subendocardial region of the heart, further supporting the notion that systemic changes in catecholamine levels are not the mechanism of PlAR downregulation seen in heart failure.58 A recent report observed that the expression of ,BARK mRNA is increased in human heart failure.59
Although ,ARK does not phosphorylate J31AR in a cultured cell line,8 additional studies are needed to clarify its role in /31AR desensitization in vivo, since tissue types with a high degree of sympathetic innervation, such as heart, express more ,ARK than noninnervated tissues. 2 Heart failure is a multifactorial disease with many local and systemic aberrations that could impact 8lAR regulation in ways unrelated to altered catecholamine levels. Additional knowledge concerning the molecular mechanisms underlying regulation of ,BAR subtypes will be necessary to fully understand the mechanisms mediating regulation of flAR responsiveness in both the normal and the diseased heart.
